サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1166117

降圧薬の世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Anti-Hypertensive Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
降圧薬の世界市場 - 成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月03日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

降圧薬市場の主な促進要因は、人口増加やライフスタイルの変化に伴う慢性疾患の蔓延、治療に対する意識の高まり、新薬の承認、医療費支出などです。

当レポートでは、世界の降圧薬市場について調査し、市場動向、競合情報、セグメント分析、新興動向、技術分析、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

  • レポートの説明
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の降圧薬市場
  • 世界の降圧薬市場：薬剤別（2021年）
  • 世界の降圧薬市場：地域別（2021年）
  • COVID-19の影響
  • 魅力的な投資提案：地域別（2021年）
  • 競合分析
    • 主要な降圧薬市場ベンダーの市場ポジショニング
    • 降圧薬市場ベンダーが採用する戦略
    • 主要な業界戦略

第3章 降圧薬市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 世界の降圧薬市場金額（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析

第4章 降圧薬市場：薬剤別（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 利尿薬
    • ACE阻害薬
    • ARB
    • カルシウムチャネル遮断薬
    • β - アドレナリン遮断薬
    • α - アドレナリン遮断薬
    • 中枢交感神経遮断薬
    • レニン阻害剤
    • 血管拡張薬

第5章 北米の降圧薬市場（2020年～2030年）

  • 市場概要
  • 降圧薬市場：薬剤別（2020年～2030年）
  • 降圧薬市場：地域別（2020年～2030年）
    • 北米

第6章 英国・欧州連合の降圧薬市場（2020年～2030年）

  • 市場概要
  • 降圧薬市場：薬剤別（2020年～2030年）
  • 降圧薬市場：地域別（2020年～2030年）
    • 英国・欧州連合

第7章 アジア太平洋の降圧薬市場（2020年～2030年）

  • 市場概要
  • 降圧薬市場：薬剤別（2020年～2030年）
  • 降圧薬市場：地域別（2020年～2030年）
    • アジア太平洋

第8章 ラテンアメリカの降圧薬市場（2020年～2030年）

  • 市場概要
  • 降圧薬市場：薬剤別（2020年～2030年）
  • 降圧薬市場：地域別（2020年～2030年）
    • ラテンアメリカ

第9章 中東・アフリカの降圧薬市場（2020年～2030年）

  • 市場概要
  • 降圧薬市場：薬剤別（2020年～2030年）
  • 降圧薬市場：地域別（2020年～2030年）
    • 中東・アフリカ

第10章 企業プロファイル

  • Novartis AG
  • Astra zeneca
  • Daiichyi Sankyo Co. Ltd
  • Takeda Pharmaceutical
  • Sanofi
  • Merck & Co
  • Boehinger Ingelheim
  • Pfizer
  • Bayer AG
  • Lupin Limited
  • Johnson & Johnson
  • Actelion Ltd
  • Ranbaxy Laboratories Limited
  • その他
図表

List of Tables

  • TABLE 1 Global Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 North America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 Latin America Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Anti-Hypertensive Drugs Market By Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Anti-Hypertensive Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anti-Hypertensive Drugs Market: Quality Assurance
  • FIG. 5 Global Anti-Hypertensive Drugs Market, By Drug, 2021
  • FIG. 6 Global Anti-Hypertensive Drugs Market, By Geography, 2021
  • FIG. 7 Global Anti-Hypertensive Drugs Market, By Drug, 2021 Vs 2030, %
  • FIG. 8 U.S. Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 France Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 China Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 India Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Anti-Hypertensive Drugs Market (US$ Million), 2020 - 2030
目次
Product Code: 137290-08-22

Hypertension is most commonly observed chronic disease, which causes elevation in systolic and diastolic blood pressure, which in long term is high risk factor for coronary artery disease, heart failure, stroke etc.. The anti-hypertensive drugs are used to control the blood pressure. The antihypertensive drugs market major drivers is the prevalence of the chronic disease along with growing population and altering lifestyle, with increase in awareness of treatment, new drug approval and healthcare expenditure.

The report titled "Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities and Competitive Analysis, 2022-2030" offers strategic insights into the overall anti-hypertensive drugs market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug class and different geographical region. The Drug class type segment studied for analyzing the overall anti-hypertensive drugs market is majorly segmented into Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global anti-hypertensive drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global anti-hypertensive drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global anti-hypertensive drugs market. In-depth competitive environment analysis and historical years (2020 & 2021) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global anti-hypertensive drug market, offering market size and estimates for the period from 2022 to 2030, keeping in mind the above-mentioned factors.

The global Anti-Hypertensive Drugs market is segmented by drug class into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. The ACE inhibitors controls the blood pressure by the by widening the blood vessel, which improve the blood flood of the heart. ACE inhibitor dominates the market share of the antihypertensive drugs market in value due to its mechanism of action, preference in geriatric population and cost. The next followed is beta blockers in antihypertensive drugs market which preferred by physician to reduce the blood pressure and risk of complication which is generally associated with chronic hypertension is less, plus with minimal side effects. Diuretic is next most commonly used anti-hypertensive drug in the market, as they are widely available and less expensive compared to others. The diuretics help in maintain the blood pressure by getting rid of the sodium and water. Diuretic is conventionally used first line of treatment, though the trend is changing with new drug entrants approval and different mechanism of action which is further preferred by physician depending upon the suitability of the patient medical history; due to which ACE, Beta blocker, CCB, ARB etc. are used now-days and exist in market according to patient needs.

The global anti-hypertensive drugs market is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America and Middle East. The global Anti-Hypertensive Drug market is dominated by the North America region occupying the major market. The major contributor in this region is US due to factors such as the prevalence of hypertension, rise in geriatric population, upcoming new drug in pipeline and use of combination therapy. Europe is next followed up market with major contributor being UK, Germany, France, Italy and Spain. According to research studies, with rise in population of Europe, there is considerable increase in number of people suffering from hypertension, therefore to address the unmet need for appropriate health care planning and expenditure are the major driving factors for the European market. The Asia-pacific is the lucrative market, with major contributors being Japan, India and China. Asia-Pacific carries almost half of the world cardiovascular burden, in which upto 66% of subtype of CVD contribute to hypertension due to increase in urbanization and adoption of unhealthy lifestyle and food. Thus developed countries dominates the market of hypertensive, emerging economies with growing population and increasing government spending on health care is lucrative market.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-Hypertensive Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anti-Hypertensive Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Diuretics

ACE inhibitors

ARBs

Calcium Channel Blockers

Beta - Adrenergic blocker

Alpha - Adrenergic blocker

Central Sympatholyics

Renin inhibitors

Vasodilators

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anti-Hypertensive Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anti-Hypertensive Drugs market?

Which is the largest regional market for Anti-Hypertensive Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anti-Hypertensive Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-Hypertensive Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anti-Hypertensive Drugs Market
  • 2.2. Global Anti-Hypertensive Drugs Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Anti-Hypertensive Drugs Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Anti-Hypertensive Drugs Market Vendors
    • 2.6.2. Strategies Adopted by Anti-Hypertensive Drugs Market Vendors
    • 2.6.3. Key Industry Strategies

3. Anti-Hypertensive Drugs Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Anti-Hypertensive Drugs Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Diuretics
    • 4.3.2. ACE inhibitors
    • 4.3.3. ARBs
    • 4.3.4. Calcium Channel Blockers
    • 4.3.5. Beta - Adrenergic blocker
    • 4.3.6. Alpha - Adrenergic blocker
    • 4.3.7. Central Sympatholyics
    • 4.3.8. Renin inhibitors
    • 4.3.9. Vasodilators

5. North America Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
  • 5.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Anti-Hypertensive Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anti-Hypertensive Drugs Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Anti-Hypertensive Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Novartis AG
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Astra zeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Daiichyi Sankyo Co. Ltd
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Takeda Pharmaceutical
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Sanofi
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Merck & Co
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Boehinger Ingelheim
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Pfizer
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Bayer AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Lupin Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Johnson & Johnson
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Actelion Ltd
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives
  • 10.13. Ranbaxy Laboratories Limited
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Initiatives
  • 10.14. Other Notable Players
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Portfolio
    • 10.14.4. Strategic Initiatives